Quatité du traitement après infarctus du myocarde: impact de recommandations hospitalières [Quality of treatment after myocardial infarction: impact of hospital guidelines].

Détails

ID Serval
serval:BIB_07DE80C97A2A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Quatité du traitement après infarctus du myocarde: impact de recommandations hospitalières [Quality of treatment after myocardial infarction: impact of hospital guidelines].
Périodique
Revue Médicale Suisse
Auteur(s)
von Gunten V., Sierro C., Rosiak S., Weibel M.L., Petignat P.A., Girod G., Beney J.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2013
Volume
9
Numéro
406
Pages
2107-2111
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
After myocardial infarction (MI), international societies of cardiology recommend an optimal treatment associating four classes of drugs, known as BASI combination (beta-blocker, antiplatelets, statin and inhibitor of the angiotensin converting enzyme). This study shows that the implementation of locally adapted guidelines in a regional hospital (CHCVs, Sion) significantly improve the treatment quality after MI, with a 10% increase of the BASI combination at discharge. Detailed results are discussed. Finally, we provide a table summarizing the optimal treatment strategy with drug examples including doses, which will be helpful to both general practitioners and specialists.
Mots-clé
Adrenergic beta-Antagonists/administration & dosage, Adrenergic beta-Antagonists/therapeutic use, Aged, Angiotensin-Converting Enzyme Inhibitors/administration & dosage, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Drug Therapy, Combination, Female, Hospitals/standards, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Male, Myocardial Infarction/drug therapy, Platelet Aggregation Inhibitors/administration & dosage, Platelet Aggregation Inhibitors/therapeutic use, Practice Guidelines as Topic, Quality of Health Care, Retrospective Studies, Societies, Medical
Pubmed
Création de la notice
12/08/2014 14:52
Dernière modification de la notice
20/08/2019 13:30
Données d'usage